Berger Mitchell B, Morgan Daniel M
Division of Gynecology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI 48109-5276, USA.
Female Pelvic Med Reconstr Surg. 2012 Sep-Oct;18(5):303-5. doi: 10.1097/SPV.0b013e318264c8e0.
Periurethral masses after injection of Durasphere bulking material have been previously reported to occur within 12 to 18 months of administration of the agent.
We present a case report of an anterior vaginal wall mass resulting from a pseudoabscess containing Durasphere agent 5 years after injection. A literature review of urethral bulking agent complications and imaging is also provided.
The patient's anterior vaginal wall mass was thought to be due to a pseudoabscess secondary to injection of bulking agent. Pelvic imaging was helpful both in identifying the mass and in surgical planning. The patient was successfully treated by outpatient transvaginal resection of the material.
Urethral bulking agents, although generally safe and effective in the treatment of stress urinary incontinence, can lead to formation of pseudoabscesses. Although these are usually recognized within the first 18 months after injection, they may not be identified until several years later.
先前有报道称，注射杜拉球囊填充材料后，尿道周围肿块会在用药后12至18个月内出现。
我们报告一例注射杜拉球囊填充材料5年后，因含该材料的假性脓肿导致阴道前壁肿块的病例。同时还提供了尿道填充剂并发症及影像学的文献综述。
患者的阴道前壁肿块被认为是由注射填充剂继发的假性脓肿所致。盆腔影像学检查有助于识别肿块及手术规划。患者通过门诊经阴道切除该材料获得成功治疗。
尿道填充剂虽然在治疗压力性尿失禁方面通常安全有效，但可导致假性脓肿形成。虽然这些通常在注射后的前18个月内被发现，但可能直到数年之后才被识别。
